For treatment-naïve adults with HIV-1. See Full Indication.
48-WEEK DATA VIDEO FOR DOVATO
Phase 3 Clinical Trial Data From GEMINI 1 & 2
Dr. W David Hardy, MD discusses the results of this dolutegravir-based, 2-drug regimen from the GEMINI 1 & 2 trials—two robust phase 3 clinical trials in 1433 treatment-naïve adult patients with HIV-1 (pooled data). In the video Dr. Hardy will be discussing the 48-week data, including virologic response, resistance results, adverse drug reactions, and discontinuations rates due to adverse events. Dr. Hardy is a paid consultant and speaker on behalf of ViiV Healthcare.